Stent Thrombosis in the Real World 

Original title: Incidence and predictors of stent trombosis: a single-centre study of 5833 consecutive patients undergoing coronary artery stenting Reference: Javaid Iqbal et al. EuroInterventional 2013;9:62-69

Though potentially fatal, stent thrombosis is a low frequency event associated to stent malapposition, fractures, resistance to antiplatelet therapies, and diseases such as diabetes and kidney disease, among other factors. 5883 pacients were analyzed retrospectively; all patients underwent PCI between 2007 and 2010 at one center. 61% of patients were admitted with AMI and 2.1% presented cardiogenic shock at procedure. The number of implanted stents was 1.6/patient, 51% were DES. Follow up was at 700 days (341-1122).

109 patients (1.9%) presented stent thrombosis (70 definite and 39 probable). All cases of definite thrombosis were confirmed by angiography except for one that was confirmed by autopsy. 80% presented ST elevation AMI, the rest with unstable angina. In patients with probable ST thrombosis, 60% presented as death, 27% as infarction and 13% as unstable angina. Population mortality in this period was 6.1%, the highest presented with thrombosis (48.6% vs 5.3% p<0.001).

Independent predictors of probable or definite thrombosis were: cardiogenic shock, clinical presentation, lack of dual antiplatelet therapy, diabetes, stent length and diameter and three vessels disease. Cardiogenic shock was strongly associated with STEMI.

Conclusion: 

Definite ST incidence in this real world registry is 1.9%. Cardiogenic shock is a strong predictor of stent thrombosis.

Commentary: 

As controlled studies show (SCAAR, ESTROFA, etc), definite or probable ST in the “real world” continues to be lower than 2%, and lower than 1% when using Everolimus DES, but with high mortality rate. Cardiogenic shock is a particular situation, excluded from most studies, most certainly due to clinical and hemodynamic conditions. Correct stent implantation is essential to reduce stent thrombosis rates. 

Courtesy of Dr Carlos Fava.
Interventional Cardiologist
Favaloro Foundation. Argentina. 

Dr. Carlos Fava para SOLACI.ORG

More articles by this author

Patients at High Risk of Bleeding After Coronary Angioplasty: Are Risk Assessment Tools ARC-HBR and PRECISE-DAPT Useful?

Patients undergoing coronary stenting typically receive dual antiplatelet therapy (DAPT) for 6 to 12 months, consisting of a P2Y12 receptor inhibitor and aspirin. While DAPT...

ACC 2025 | WARRIOR: Ischemia in Women with Non-Obstructive Coronary Artery Disease

Approximately half of all women with symptomatic ischemia who undergo coronary angiography are found to have non-obstructive coronary artery disease ((ischemia and non-obstructive coronary...

ACC 2025 | FLAVOUR II: Angiography-Derived FFR-Guided vs. IVUS-Guided PCI

Physiological assessment is effective when it comes to decision-making for percutaneous coronary intervention (PCI). However, despite the available evidence, its use remains limited. AngioFFR...

ACC-2025 Congress Second Day Key Studies

BHF PROTECT-TAVI (Kharbanda RK, Kennedy J, Dodd M, et al.)The largest randomized  trial carried out across 33 UK centers between 2020 and 2024, assessing...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Patients at High Risk of Bleeding After Coronary Angioplasty: Are Risk Assessment Tools ARC-HBR and PRECISE-DAPT Useful?

Patients undergoing coronary stenting typically receive dual antiplatelet therapy (DAPT) for 6 to 12 months, consisting of a P2Y12 receptor inhibitor and aspirin. While DAPT...

ACC 2025 | WARRIOR: Ischemia in Women with Non-Obstructive Coronary Artery Disease

Approximately half of all women with symptomatic ischemia who undergo coronary angiography are found to have non-obstructive coronary artery disease ((ischemia and non-obstructive coronary...

ACC 2025 | TAVI in Low-Risk Patients: 5-Year Outcomes of EVOLUTE LOW RISK

Transcatheter aortic valve implantation (TAVI) is a valid alternative to surgery in low-risk patients with severe aortic stenosis. However, one of its main limitations...